Table 3 Summary of clinical courses
Case | Treatment | Response to treatment | Overall survival duration (months) | Relapse | Outcome | Cause of death |
|---|---|---|---|---|---|---|
 1 | R-CHOP ×5 | PR | 45.0 | No | Dead | Cholangiocarcinoma |
(75% dose) | ||||||
 2 | R-CHOP ×6 | PR | 7.9 | No | Dead | Pneumonia |
IT* | ||||||
 3 | R-CHOP ×2 | NA | 4.0 | − | Dead | Exacerbation of pulmonary fibrosis |
(70% dose) | ||||||
 4 | R-MPV ×4 | CR | 40.1 | No | Alive | − |
IT* | ||||||
HD-Ara-C ×2 | ||||||
WBRT | ||||||
 5 | R-CHOP ×6 | CR | 28.0 | No | Alive | − |
HD-MTX ×2 | ||||||
IT* | ||||||
 6 | R-CHOP ×8 | CR | 24.8 | No | Alive | − |
IT* | ||||||
 7 | R-COP ×1 | NA | 2.6 | − | Dead | Pneumonia |
(60% dose) |